The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis / van der Holt B; Lowenberg B; Burnett AK; Knauf WU; Shepherd J; Piccaluga PP; Ossenkoppele GJ; Verhoef GE; Ferrant A; Crump M; Selleslag D; Theobald M; Fey MF; Vellenga E; Dugan M; Sonneveld P.. - In: BLOOD. - ISSN 0006-4971. - STAMPA. - 106:(2005), pp. 2646-2654. [10.1182/blood-2005-04-1395]
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
PICCALUGA, PIER PAOLO;
2005
File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
